Siltuximab: Difference between revisions

Latest revision as of 13:10, 18 March 2025

Siltuximab (Sylvant) is an interleukin-6 (IL-6) antagonist used for the treatment of patients with multicentric Castleman's disease (MCD).

This medicine is used to treat people with multicentric Castleman's disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors.
IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion.
Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.

This medicine cannot be used in patients with:

Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in patients treated with Sylvant may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment with Sylvant.

Recommended Dosage:

Administer Sylvant 11 mg/kg over 1 hour as an intravenous infusion every 3 weeks until treatment failure.

Administration

This medicine is available in fallowing doasage form: As injection

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Sylvant may cause serious side effects, including:

Do not administer Sylvant to patients with severe infections, monitor for infections, institute prompt treatment, and interrupt Sylvant until resolution of infection.
Do not administer live vaccines because IL-6 inhibition may interfere with the normal immune response to new antigens.
Sylvant may cause infusion related reactions and anaphylaxis. Administer Sylvant in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.
Gastrointestinal (GI) perforation has been reported in clinical trials. Promptly evaluate patients presenting with symptoms that may be associated or suggestive of GI perforation.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

The limited available information on Sylvant use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage.

The safety and efficacy of Sylvant have not been established in pediatric patients.

Active ingredient: siltuximab
Inactive ingredients: L-histidine and L-histidine monohydrochloride monohydrate, polysorbate 80, and sucrose

Manufactured by:

Sylvant must be refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
Do not freeze.
Do not use Sylvant beyond the expiration date (EXP) located on the carton and the vial.

Revision as of 09:51, 30 August 2022 edit Deepika vegiraju (talk \| contribs) administrator, Bureaucrats, emailconfirmed, Interface administrators, smwadministrator, Administrators 7,811 edits No edit summary		Latest revision as of 13:10, 18 March 2025 edit undo Prab (talk \| contribs) , Bureaucrats, Interface administrators, Administrators 1,432,229 edits No edit summary
(2 intermediate revisions by the same user not shown)
Line 137:		Line 137:

	[[Category:Monoclonal antibodies]]		[[Category:Monoclonal antibodies]]
			{{No image}}